期刊文献+

伊布利特转复房扑及房颤的临床研究 被引量:8

Clinical Study of Ibutilide in TermInation of Atrial Fibrillation and Atrial Flutter
下载PDF
导出
摘要 目的探讨静脉应用伊布利特转复心房颤动/心房扑动的有效性。方法筛选持续时间在90 d以内,符合入选条件的阵发或持续性房颤/房扑患者共36例,随机分为伊布利特组和可达龙组各19例和17例。伊布利特组体重≥60 kg者,首剂1.0 mg稀释于0.9%氯化钠注射液20 mL静脉推注;体重<60 kg者,首剂0.01 mg/kg,如无效10 min后再给予1.0 mg/kg或0.01 mg/kg;可达龙组,首剂150 mg稀释于0.9%氯化钠注射液20 mL静脉推注,如无效10 min后再给予150 mg。结果伊布利特组和可达龙组的总转复率分别为63.16%VS 35.29%(P<0.05);伊布利特组房扑的转复率明显高于可达龙组75.0%VS 33.3%(P<0.01),伊布利特组房颤的转复率明显高于可达龙组60%VS 35.71%(P<0.05),差异均有统计学意义。伊布利特组和可达龙组平均转复时间分别为(28.13±11.46)min VS(50.01±14.72)min,差异有统计学意义(P<0.01)。两组均能有效降低房颤/房扑的心室率,但组间比较差异无统计学意义。结论伊布利特是一种起效快,对房扑、房颤患者转复率高的药物,其疗效优于可达龙,但需在严格监控下进行。 Objective To investigate the efficacy of intravenous ibutilide for conversion of atrial fibrillation (AF) and flutter (AFL) to nomlal sinus rhythm. Methods Thirty- six consecutive patients with AF or AFL were included. The duration of arrhythmia was less than 90 days. Ibutilide group( 19 patients) and amiodarone group ( 17 patients) were assigned randomly. Patients in ibutilide group received 1.0 mg ibutilide when body weight ≥60 kg or 0.01 mg/kg when body weight 〈 60 kg; treatment was repeated if atrial fibrillation or flutter was not converted 10 min after the first dosage. Patients in the amiodarone group received 150 mg amiodarone, followed by a further 150 mg if atrial fibrillation or flutter persisted 10 min after the first dosage. Two drugs were diluted by 20 mL of 0.9% sodium chloride and injected intravenously within 10 min. Results The overall conversion rate on AFL and AF of the ibutilide group was significantly higher than that of the amiodarone group (63.16% VS 35.29%, P 〈 0.05). The conversion rate on AFL of the ibutilide group was significantly higher than that of the amiodarone group(75.0% VS 33.3%, P 〈 0.01 ), The conversion rate on AF of the ibutilide group was significantly higher than that of the anfiodarone group (60.0% VS 35.71 %, P 〈 0.05). Ibutilide had a significantly fast the mean converting time than amiodarone (28.13 ± 11.46) min vs (50.01 ± 14.72) min ( P 〈 0.01 ). Both two drugs decreased ventrieular rate, but there was not significant difference at group comparison. Conclusion Ibutilide is a rapid and effective drug with high rate of conversion for atrial fibrillation and atrial flutter, which is more effective than amiodarone. The administration should be carried out under strict eleetrocardio monitoring.
出处 《黑龙江医学》 2009年第10期732-735,共4页 Heilongjiang Medical Journal
关键词 伊布利特 心房扑动 心房颤动 药物转复 Ibutilide Atrial fibrillation Atrial flutter Drug cardioversion
  • 相关文献

参考文献1

二级参考文献20

  • 1Naccarelli GV,Lee KS,Gibson JK,et al.Electrophysiology and pharmacology of ibutilide.Am J Cardiol,1996,78:12-16.
  • 2Lych JR,Baskin EP,Nutt EM,et al.Comparison of binding to rapidly activating delayed rectifier K channel,Ikr and effects on myocardial refractoriness for class Ⅲ antiarrythmic agents.J Cardiovasc Pharmacol,1995,25:336-340.
  • 3Baskin EP,Lynch JJ Jr.Differential atrial versus ventricular activities of class Ⅲ potassium channel blockers.Pharmacol Exp Ther,1998,285:135-142.
  • 4Stambler BS,Beckman KJ,Kardish AH,et al.Acute hemodynamic effects of intravenous Ibutilide in patients with or without reduced left ventricular function.Am J Cardiol,1997,80:458- 463.
  • 5Stambler BS,Wood MA,Ellenbogen KA,et al.Antiarrhymic actions of intravenous Ibutilide compared with procaimamide during human atrial flutter and fibrillation:electrophysilogical determinants of enhanced conversion efficacy.Circulation,1997,96,4298- 4306.
  • 6Volgman AS,Stambler BS,Kappagoda C,et al.Comparison of intravenous Ibutilide versus procainainamide for rapid termination of atrial flutter or fibrillation.PACE,1996,19:608.
  • 7Kannel WB,Abbott RD,Savage DD,et al.Epidemiologic features of chronic atrial fibrillation:the Framingham study.N Engl J Med,1982,306:1018-1022.
  • 8Wijffels MECF,Kirchof CJHJ,Dorland R,et al.Atrial fibrillation begets atrial fibrillation.A study in awake chronically instrumented goats.Circulation,1995,92:1954-1968.
  • 9Cropp JS,Antal EG,Talbert RL,et al.Ibutilide:a new class Ⅲ antiarrhythmic agent.Parmarcotherapy,1997,17:1-9.
  • 10Vos MA,Golitsyn SR,Stangl K,et al.Superiority of ibutilide (a new class Ⅲ agent) over DL-sotalol in converting atrial flutter and atrial fibrillation.Heart,1998,79:568-575.

共引文献12

同被引文献152

引证文献8

二级引证文献58

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部